- The study addressed the challenge of optimal risk stratification for individuals with subjective cognitive decline (SCD) to predict progression to mild cognitive impairment (MCI) or dementia.
- Researchers conducted a longitudinal observational study involving 469 participants with SCD from the BioFINDER-1 and BioFINDER-2 cohorts, with follow-up data over 4.0 ± 2.1 years.
- A model combining plasma phosphorylated tau 217 (p-tau217), cognitive scores, and apolipoprotein E epsilon 4 (APOE4) status demonstrated excellent predictive ability for Alzheimer disease dementia (C-index = 0.91 ± 0.009).
- The authors concluded that a clinically feasible multimodal approach, including cognitive assessment, plasma p-tau217, and APOE4 status, accurately predicts Alzheimer disease dementia risk in individuals with SCD.
- These findings underscore the clinical value of plasma p-tau217 in refining risk assessment in memory clinic settings, potentially guiding early interventions and clinical trial selection.
Navigating the Future: Risk Assessment in Subjective Cognitive Decline
Subjective cognitive decline (SCD), a patient's self-reported sense of worsening cognition without objective deficits on standard testing, is a common and challenging clinical presentation. While many individuals with SCD remain stable, a significant subset will progress to mild cognitive impairment (MCI) or Alzheimer disease (AD) dementia, making accurate risk stratification a critical need for patient counseling, early intervention, and clinical trial enrollment [1, 2, 3, 4, 5, 6]. A recent longitudinal study provides new clarity on how to combine clinical, genetic, and biomarker data to more precisely identify which patients with SCD are at highest risk of progression.
Study Design and Participant Characteristics
This longitudinal observational study evaluated how a combination of biomarkers could predict cognitive progression in individuals with SCD. The researchers analyzed data from two large cohorts, BioFINDER-1 and BioFINDER-2, creating a final sample of 469 participants with SCD. The group had a mean age of 69.1 ± 7.1 years, and 51.4% were female. To ensure the robustness of their analysis in the face of real-world data imperfections, the authors used multiple imputation, a statistical method for handling missing data points. The primary goal was to forecast progression to all-cause dementia, AD dementia, or MCI over time.
Progression Rates and Differentiating Factors
Over a mean follow-up of 4.0 ± 2.1 years, 84 of the 469 participants (17.9%) progressed to dementia. The study confirmed that a substantial portion of this progression was due to Alzheimer disease, as 66.7% of those who developed dementia were diagnosed with AD dementia. The analysis identified a clear profile of individuals at higher risk. Compared to those who remained stable, progressors were older, more likely to be APOE4 carriers, and had worse baseline cognitive scores. They also showed a distinct biological footprint, with higher plasma levels of phosphorylated tau 217 (p-tau217), a specific marker of AD pathology, and greater brain changes on MRI, including more significant atrophy and a higher burden of white matter hyperintensities, which are markers of small vessel cerebrovascular disease.
Predictive Power for Alzheimer's Dementia
In the search for the most effective predictive tools, the study evaluated biomarkers both individually and in combination. When assessed alone, plasma p-tau217 was the strongest single predictor of progression to AD dementia, achieving a Harrell C-index of 0.86 ± 0.012. The C-index is a measure of a model's ability to correctly distinguish between patients who will and will not experience an event, with 1.0 being perfect prediction and 0.5 being no better than chance. While p-tau217 alone was powerful, the authors found that multivariable models consistently provided better predictive accuracy. A clinically practical model combining plasma p-tau217, baseline cognitive scores, and APOE4 status yielded an excellent C-index of 0.91 ± 0.009 for predicting AD dementia. Critically, adding MRI markers of brain atrophy and white matter disease to this model provided only marginal improvement for predicting AD dementia specifically. This suggests that for stratifying risk for AD dementia in patients with SCD, a combination of a blood test, cognitive testing, and genetic analysis may be sufficient in many cases.
Predicting All-Cause Dementia and Mild Cognitive Impairment
The study also extended its analysis to broader clinical outcomes. For predicting progression to all-cause dementia, which includes AD as well as vascular, Lewy body, and other dementias, a more comprehensive approach was superior. The model incorporating all variables, including cognitive scores, APOE4 status, plasma p-tau217, and MRI measures of cortical thickness, hippocampal volume, and white matter hyperintensities, achieved the highest accuracy, with a C-index of 0.89 ± 0.003. This highlights that while a focused set of biomarkers is effective for AD, predicting dementia from any cause benefits from the additional information on brain structure and vascular health provided by MRI. The study also examined the earlier transition to MCI in a subset of 249 participants, where 84 progressed over 2.3 ± 1.2 years. For this earlier endpoint, predictive accuracy was generally lower, with both a plasma-focused model and the full multimodal model achieving a similar C-index of 0.83 ± 0.009.
Clinical Implications for Risk Stratification
For clinicians managing patients with subjective cognitive decline, these findings offer a structured framework for risk assessment. The study demonstrates that a combination of widely available tools, specifically cognitive testing, plasma p-tau217 measurement, and APOE4 genotyping, can accurately identify individuals at high risk of progressing to AD dementia (C-index = 0.91 ± 0.009). The high performance of this relatively accessible model supports the potential for implementing plasma p-tau217 testing in memory clinic settings to refine patient counseling and management. The results also provide important nuance. While the blood test-based model is highly effective for AD dementia risk, clinicians seeking to predict progression to all-cause dementia should consider that adding MRI measures of brain atrophy and white matter disease provides superior predictive power. This tiered approach allows for a more tailored risk assessment, helping to identify candidates for closer monitoring, lifestyle interventions, and future disease-modifying therapy trials.
References
1. Xu N, Qiu H, Mao C, Zhao L. Digital health interventions for older adults with subjective cognitive decline or mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials.. BMC geriatrics. 2026. doi:10.1186/s12877-026-07341-w
2. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004. doi:10.1111/j.1365-2796.2004.01380.x
3. Marafioti G, Culicetto L, Latella D, Marra A, Quartarone A, Buono VL. Neural correlates of subjective cognitive decline in Alzheimer’s disease: a systematic review of structural and functional brain changes for early diagnosis and intervention. Frontiers in Aging Neuroscience. 2025. doi:10.3389/fnagi.2025.1549134
4. Jack CR, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer s & Dementia. 2018. doi:10.1016/j.jalz.2018.02.018
5. An R, Gao Y, Huang X, Yang Y, Yang C, Wan Q. Predictors of progression from subjective cognitive decline to objective cognitive impairment: A systematic review and meta-analysis of longitudinal studies.. International Journal of Nursing Studies. 2023. doi:10.1016/j.ijnurstu.2023.104629
6. Vasileiou D, Moraitou D, Diamantaras K, Papaliagkas V, Pezirkianidis C, Tsolaki M. Positive Psychology Interventions in Early-Stage Cognitive Decline Related to Dementia: A Systematic Review of Cognitive and Brain Functioning Outcomes of Mindfulness Interventions. Brain Science. 2025. doi:10.3390/brainsci15060580